Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

CohBar, Inc.

CohBar is a clinical stage biotechnology company whose mission is to increase healthy lifespan by developing treatments for the underlying metabolic dysfunction driving the diseases of aging including NASH, obesity, cancer, Type 2 diabetes, and cardiovascular and neurodegenerative diseases.

  • Date:Tuesday, February 12
  • Time:10:00 AM - 10:15 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23505
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:To introduce CohBar and broaden awareness within the investment community
  • Company Website:www.cohbar.com
  • Company HQ City:Menlo Park
  • Company HQ State:California
  • Company HQ Country:United States
  • Market Cap:200M
  • Ticker:CWBR
  • Exchange:NASDAQ
  • CEO/Top Company Official:Philippe Calais, Ph.D.
  • Year Founded:2009
  • Main Therapeutic Focus:Metabolic Diseases
  • Lead Product in Development:CB4211 - for NASH and Obesity
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):Numerous
Speakers
Philippe Calais
CohBar, Inc.
Back